- Home
- CELZ
as 07-26-2024 4:00pm EST
Creative Medical Technology Holdings Inc is a biotechnology holding company focused on regenerative medicine. It is formed for the purpose of creating and licensing intellectual property in the area of amniotic fluid derived stem cells for therapeutic applications. Its core activity is stem cell research and the development of applications for use to treat male and female sexual dysfunction, infertility, miscarriages, and related issues.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | PHOENIX |
| Market Cap: | 5.0M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 5.1K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.74 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.90 - $10.28 | Next Earning Date: | 08-09-2024 |
| Revenue: | $9,000 | Revenue Growth: | -87.77% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Creative Medical Technology Holdings Inc. News
CELZ Breaking Stock News: Dive into CELZ Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program
Simply Wall St.
15 days ago
Here's Why Creative Medical Technology Holdings, Inc.'s (NASDAQ:CELZ) CEO Compensation Is The Least Of Shareholders Concerns
GlobeNewswire
17 days ago
Creative Medical Technology Holdings Provides Corporate Update
GlobeNewswire
a month ago
Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin
Business Wire
4 months ago
Creative Medical Technology Holdings Provides Corporate Update
Simply Wall St.
4 months ago
Creative Medical Technology Holdings Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
Business Wire
5 months ago
Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access
Business Wire
5 months ago
Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy
Compare CELZ vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CELZ Creative Medical Technology Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.